Drug Trial Radar · NCT06824064
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 17, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Riboscience, LLC.Industry
- Sponsor type
- Industry
- Collaborators
- Tam Anh Research Institute
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).
Conditions
- Metastatic Colorectal Cancer
- Advanced Colorectal Cancer
Interventions
RBS2418Drug
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.
PlaceboDrug
Placebo to Match RBS2418
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: From randomization until the first radiographic documentation of objective progression or death from any cause, assessed up to 2 years.
- Overall SurvivalTime frame: From randomization until death from any cause, assessed up to 2 years.
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Christiana Care
Newark, Delaware · Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada · Recruiting
SCRI Oncology LLC
Nashville, Tennessee · Recruiting
Community Clinical Trials
Kingwood, Texas · Recruiting
Pan Oncology
San Juan, Puerto Rico · Recruiting
Oncology Hospital
Ho Chi Minh City, Vietnam · Recruiting
Tam Anh, Ha Noi General Hospital
Hanoi, Hanoi, Vietnam · Recruiting
Tam Anh TP. Ho Chi Minh General Hospital
Ho Chi Minh City, Ho Chi Minh City, Vietnam · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.